<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Drugs</journal-id><journal-id journal-id-type="iso-abbrev">CNS Drugs</journal-id><journal-title-group><journal-title>CNS Drugs</journal-title></journal-title-group><issn pub-type="ppub">1172-7047</issn><issn pub-type="epub">1179-1934</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4246125</article-id><article-id pub-id-type="publisher-id">212</article-id><article-id pub-id-type="doi">10.1007/s40263-014-0212-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Authors&#x02019; Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ignatowski</surname><given-names>Tracey A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Spengler</surname><given-names>Robert N.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tobinick</surname><given-names>Edward</given-names></name><address><phone>(561) 353-9707</phone><email>nrimed@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Department of Pathology and Anatomical Sciences and Program for Neuroscience, School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY USA </aff><aff id="Aff2"><label/>NanoAxis, LLC, Clarence, NY USA </aff><aff id="Aff3"><label/>Institute of Neurological Recovery, 2300 Glades Road Suite 305E, Boca Raton, FL 33431 USA </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>28</volume><issue>12</issue><fpage>1207</fpage><lpage>1213</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The authors of this article have each been involved, over the course of more than a decade, in the basic science and/or clinical investigation of tumor necrosis factor (TNF) mechanisms involving the brain, i.e. in neuroinflammation research [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. One of the aims of our 2014 review was to bring together the increasing scientific evidence, from multiple fields of investigation and multiple academic centers that support a central role of neuroinflammation in the pathogenesis of post-stroke neurological dysfunction [<xref ref-type="bibr" rid="CR17">17</xref>]. In 2014, neuroinflammation has emerged as an area of increased international research interest, with intense interest in Europe and a new neurology journal devoted to this specific field [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Novel scientific discoveries, synthesized with previous scientific evidence, provide a framework for the scientific rationale underlying the rapid effects of perispinal etanercept on brain pathology [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. This framework includes the discovery, in 2011, through the use of functional magnetic resonance imaging (fMRI), that within 24&#x000a0;h after neutralization of TNF by systemic intravenous administration of infliximab, nociceptive activity in the thalamus and somatosenoric cortex, as well as activation of the limbic system, was blocked [<xref ref-type="bibr" rid="CR22">22</xref>]. In 2013, a single systemic subcutaneous dose of another biologic TNF inhibitor, certolizumab pegol, was found to produce a rapid decrease in disease-related fMRI brain activity in rheumatoid arthritis patients, which preceded both clinical and structural responses to the drug [<xref ref-type="bibr" rid="CR28">28</xref>]. Just this week it was reported that a single dose of an antidepressant, the selective serotonin reuptake inhibitor escitalopram, dramatically alters functional connectivity throughout the whole brain in healthy subjects within 3&#x000a0;hours of the dose [<xref ref-type="bibr" rid="CR23">23</xref>]. The rapid and profound effect that antidepressant drugs have on the production of TNF in the brain was&#x000a0;first demonstrated by Ignatowski and Spengler in 1994 [<xref ref-type="bibr" rid="CR29">29</xref>]. Antidepressant administration (desipramine) to rats prevented neuron-associated TNF production, as demonstrated by staining for TNF in the locus coeruleus and hippocampus [<xref ref-type="bibr" rid="CR30">30</xref>]. This was demonstrated to occur within 24&#x000a0;h after drug administration [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. These findings, along with the scientific evidence previously considered in our 2014 review, demonstrate that rapid effects of perispinal etanercept are entirely compatible with brain physiology as it is understood today [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Whitlock has written a letter commenting on our 2014 review [<xref ref-type="bibr" rid="CR38">38</xref>], which begins with a misconception regarding the well-known criteria that Sir Austin Bradford Hill originally developed to facilitate evaluation of causality [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. We utilized the Hill criteria in our 2014 review [<xref ref-type="bibr" rid="CR17">17</xref>]. Contrary to the assertion of Whitlock, expert opinion supports use of the Bradford Hill criteria as one method to assist in the evaluation of the strength of evidence supporting therapeutic causality [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. This modification of the Hill criteria for therapeutic evaluation was not the authors&#x02019; invention; rather, this use of the Hill criteria was suggested by central figures in the evidence-based medicine paradigm (Howick and Glasziou) and others [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. As Williams observed in 2001:<disp-quote><p>The narrow definition of epidemiology is the study of the distribution of diseases in a population. The broader definition&#x02014;an inductive science of biological inferences derived from observations&#x02014;is more appropriate when relating EBM principals to clinical decision making &#x02026;&#x000a0;. The use of Bradford-Hill Criteria enhances evidence-based recommendations [<xref ref-type="bibr" rid="CR42">42</xref>].</p></disp-quote></p><p>Explicit consideration of the Bradford Hill criteria may facilitate appreciation of the scientific rationale and evidence regarding pathophysiology underlying innovative therapeutic decision making [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p>Randomized clinical trial (RCT) evidence is essential for regulatory approval but RCTs that involve innovative methods of drug delivery may only be possible with direct involvement of the drug manufacturer [<xref ref-type="bibr" rid="CR46">46</xref>]. A blind insistence that the RCT constitutes the only valid form of evidence, as Whitlock suggests, does a disservice to science and the public [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. The discovery of a new use of an existing drug often begins with an initial observation made in the course of clinical practice when utilizing the drug off-label [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Evidence development commonly involves open-label observational studies; this was the case for the first approved indication of the biologic TNF inhibitors [<xref ref-type="bibr" rid="CR55">55</xref>]. Rigorous observational studies, including case studies and case series, are a classical approach that may provide early evidence for therapeutic effectiveness before formal RCTs are conducted [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>]. It is not scientifically justifiable to ignore the valid evidence contained in observational studies when evaluating therapeutic interventions, particularly for emerging indications [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. As multiple authors have stated:<disp-quote><p>Sometimes the effect of a medical intervention is so surprisingly strong, against the background knowledge of &#x02018;usual prognosis&#x02019;, that a case report or case series suffices to convince [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p>Case reports and case series have their own role in the progress of medical science. They permit discovery of new diseases and unexpected effects (adverse or beneficial) as well as the study of mechanisms, and they play an important role in medical education. Case reports and series have a high sensitivity for detecting novelty and therefore remain one of the cornerstones of medical progress; they provide many new ideas in medicine [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p>Given that randomized, controlled trials have not and often cannot be done for many clinical interventions, much of the clinical care provided in neurology (and all other specialties in medicine) would necessarily be considered unsubstantiated, if observational studies are discounted from consideration &#x02026; the popular belief that randomized, controlled trials inherently produce gold standard results, and that all observational studies are inferior, does a disservice to patient care, clinical investigation, and education of health care professionals [<xref ref-type="bibr" rid="CR49">49</xref>].</p></disp-quote></p><p>As recently restated in an opinion viewpoint published in <italic>JAMA Neurology</italic>, &#x0201c;&#x02026; over-reliance on RCTs is similar to resting all of health care evidence on a one-legged stool&#x0201d; [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. The authors concluded:<disp-quote><p>&#x0201c;Most health care decisions, especially by clinicians and patients, are based on incomplete evidence. This process could be improved with better access to transparent, credible, and concise yet complete summaries of the available evidence and its strength, whether or not it is conclusive and whether or not it includes RCTs&#x0201d; [<xref ref-type="bibr" rid="CR47">47</xref>].</p></disp-quote></p><p>Authorities in the field of evidence-based medicine have specifically addressed the fact that some treatments have effects that are &#x0201c;&#x02026; so dramatic that randomised trials are unnecessary<italic>&#x0201d;</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]. Each of the authors has personally observed the unmistakable rapid neurological improvement produced by perispinal etanercept in patients with chronic, stable, baseline neurological dysfunction [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The distinctive pattern of neurological improvement that often ensues following perispinal etanercept injection, documented in published digital video and written format, provides striking scientific evidence of a therapeutic effect [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR62">62</xref>].<xref ref-type="fn" rid="Fn1">1</xref> These results are supported by a diverse variety of additional clinical and basic science studies that have specifically utilized etanercept as a therapeutic agent [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>]. Our recent review presents a detailed overview of the scientific evidence that supports the mechanistic reasoning utilized [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. There are no gaps in the pathophysiological mechanisms discussed; the inferential chain is complete [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The published, peer-reviewed perispinal etanercept scientific literature provides more than a decade of scientific support that includes detailed case studies documenting rapid and sustained neurological improvement in patients with neurological dysfunction that had long been unchanged prior to perispinal etanercept administration [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR74">74</xref>&#x02013;<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR82">82</xref>].</p><p>These case reports are not isolated cases. Rather these results have been replicated, confirmed and extended [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Four years of clinical experience with many additional patients with chronic brain dysfunction after stroke, intracerebral hemorrhage, and acquired brain injury has followed the documented pattern of statistically significant improvements in motor impairment, cognition, psychological/behavioural function, aphasia and pain following perispinal etanercept injection reported in the 629-patient study of 2012 [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Moreover, since publication of the 2012 study [<xref ref-type="bibr" rid="CR26">26</xref>], the peer-reviewed medical literature has provided further basic science and clinical support for the scientific rationale [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR83">83</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref>]. As Lei et. al. and Kathirvelu and Carmichael stated in 2013 and 2014, respectively:<disp-quote><p>Antagonism of pro-inflammatory cytokines by specific antibodies represents a compelling therapeutic strategy to improve neurological outcome in patients after intracerebral hemorrhage [<xref ref-type="bibr" rid="CR107">107</xref>].</p><p>With direct blood extravasation into brain, secondary inflammation is a substantial feature. Drugs which reduce neuroinflammation enhance functional recovery [<xref ref-type="bibr" rid="CR94">94</xref>].</p></disp-quote></p><p>As a noted authority in the field of TNF and brain dysfunction has written:<disp-quote><p>&#x02026; the years-long interval between the stroke event and rapid clinical improvement described in these patients is consistent with experimental evidence that TNF generation persists in the CSF for very much longer (10&#x000a0;months plus) than in the serum (gone in 6&#x000a0;h)&#x02026;. In this report each patient&#x02019;s pre-treatment state provided an internal control. In practice, these individual pre-treatment comparisons are highly valid, since the likelihood of rapid spontaneous return of function is remote this long after the stroke event. Moreover, since no two stroke outcomes are the same, such internal controls allow precise before and after clinical comparison in a phenotypically heterogeneous condition [<xref ref-type="bibr" rid="CR121">121</xref>].</p></disp-quote></p><p>There are now multiple, reported RCTs of etanercept for neurological indications that have shown etanercept to be superior to placebo [<xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. The character, magnitude and reproducibility of patient recovery documented following perispinal etanercept for chronic post-stroke neurological dysfunction is unequivocal evidence of a therapeutic effect [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR74">74</xref>].</p><p>Whitlock further errs in his analogy comparing the effects of opiates and etanercept for neuropathic pain [<xref ref-type="bibr" rid="CR38">38</xref>]. Exerting physiological effects that are distinct from those produced by opiates, TNF blockade using etanercept for treatment of neuropathic pain is a disease-modifying therapy that directly addresses a fundamental cause of the disorder, i.e. excess TNF [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. The authors each reported favorable effects of TNF blockade for the treatment of neuropathic pain, beginning more than a decade ago [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. To date, there are four favorable double-blind, randomized controlled trials of etanercept for sciatica and other forms of spinal neuropathic pain that have been completed [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. In addition, the basic science evidence supporting a therapeutic, disease-modifying effect of etanercept for the treatment of neuropathic pain continues to increase [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. It is of significant interest that recent evidence suggests that the early analgesic effects of biologic TNF inhibitors in patients with rheumatoid arthritis may be directly mediated, not peripherally but rather by rapid brain effects of the biologic TNF inhibitor [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>The rapid and dramatic neurological improvement repeatedly observed after perispinal etanercept administration in patients with chronic, post-stroke neurological dysfunction cannot be scientifically attributed to a placebo response, as Whitlock seems to suggest [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR100">100</xref>, <xref ref-type="bibr" rid="CR118">118</xref>, <xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR124">124</xref>]. In fact, a recent Cochrane review concluded:<disp-quote><p>There was no evidence that placebo interventions in general have clinically important effects [<xref ref-type="bibr" rid="CR124">124</xref>].</p></disp-quote></p><p>Placebo effects do not produce the life-changing neurological improvements that have been documented and observed by each of the authors and others following perispinal etanercept injection [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. In view of the distinctive character, quality and reproducibility of the clinical data, and the basic science evidence that supports the entire inferential chain, it would be a systematic error to deny the published, peer-reviewed evidence and characterize the reported clinical results of perispinal etanercept for post-stroke neurological dysfunction as anything less than a therapeutic breakthrough [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref>]. Those scientists who have recognized TNF antagonism for this indication as a &#x0201c;compelling therapeutic strategy&#x0201d;[<xref ref-type="bibr" rid="CR107">107</xref>] are exactly in line with the guidance to &#x0201c;translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care&#x0201d; that is the published consensus recommendation of world stroke leaders [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p>Etanercept is providing billions of dollars of yearly income to its manufacturers. These drug manufacturers are the only entities that possess the combination of regulatory expertise and financial capability necessary to achieve regulatory approval for these essential novel therapeutic indications. The strength of the emerging evidence argues for joint industry&#x02013;government&#x02013;academic cooperation to facilitate overcoming the substantial translational barriers that exist for such an innovative therapeutic approach.</p></body><back><fn-group><fn id="Fn1"><label>1</label><p>Further digital video documentation at <ext-link ext-link-type="uri" xlink:href="https://vimeo.com/user5534662/review/85796991/4385338257">https://vimeo.com/user5534662/review/85796991/4385338257</ext-link>; <ext-link ext-link-type="uri" xlink:href="https://vimeo.com/user5534662/review/85477199/2aa9b2c6f8">https://vimeo.com/user5534662/review/85477199/2aa9b2c6f8</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.vimeo.com/18550399">http://www.vimeo.com/18550399</ext-link>.</p></fn></fn-group><ack><title>Acknowledgments and Conflict Disclosure</title><p>Edward Tobinick has multiple issued and pending US and foreign patents, assigned to TACT IP, LLC, which claim methods of use of etanercept for the treatment of neurological disorders, including, but not limited to, US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306 and 8349323, all assigned to TACT IP, LLC; and Australian patent 758523. Dr. Tobinick is the founder of the Institute of Neurological Recovery (INR), a group of medical practices that utilize perispinal etanercept as a therapeutic modality, and also train physicians; he is also the CEO of TACT IP, LLC. Tracey Ignatowski and Robert Spengler have been expert witnesses for the INR. Tracey Ignatowski and Robert Spengler&#x02019;s professional activities include their work as Co-Directors of Neuroscience at NanoAxis, LLC, a company formed to foster the commercial development of products and applications in the field of nanomedicine, which include novel methods of inhibiting TNF. This article represents the authors&#x02019; own work in which NanoAxis, LLC, was not involved. No funding was received for this letter.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Covey</surname><given-names>WC</given-names></name><name><surname>Knight</surname><given-names>PR</given-names></name><name><surname>Severin</surname><given-names>CM</given-names></name><name><surname>Nickola</surname><given-names>TJ</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Brain-derived TNFalpha mediates neuropathic pain</article-title><source>Brain Res</source><year>1999</year><volume>841</volume><issue>1&#x02013;2</issue><fpage>70</fpage><lpage>77</lpage><?supplied-pmid 10546989?><pub-id pub-id-type="pmid">10546989</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covey</surname><given-names>WC</given-names></name><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Knight</surname><given-names>PR</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain</article-title><source>Brain Res</source><year>2000</year><volume>859</volume><issue>1</issue><fpage>113</fpage><lpage>122</lpage><?supplied-pmid 10720620?><pub-id pub-id-type="pmid">10720620</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covey</surname><given-names>WC</given-names></name><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Renauld</surname><given-names>AE</given-names></name><name><surname>Knight</surname><given-names>PR</given-names></name><name><surname>Nader</surname><given-names>ND</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain</article-title><source>Reg Anesth Pain Med</source><year>2002</year><volume>27</volume><issue>4</issue><fpage>357</fpage><lpage>366</lpage><?supplied-pmid 12132059?><pub-id pub-id-type="pmid">12132059</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>JL</given-names></name><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor</article-title><source>J Neurosci Res</source><year>2005</year><volume>79</volume><issue>6</issue><fpage>779</fpage><lpage>787</lpage><?supplied-pmid 15672410?><pub-id pub-id-type="pmid">15672410</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Berczi</surname><given-names>I</given-names></name><name><surname>Szentivanyi</surname><given-names>A</given-names></name></person-group><article-title>Cytokines in synaptic function</article-title><source>Cytokines and the brain. NeuroImmune biology. Vol 6</source><year>2008</year><publisher-loc>Amsterdam</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>111</fpage><lpage>143</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martuscello</surname><given-names>RT</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name><name><surname>Bonoiu</surname><given-names>AC</given-names></name><name><surname>Davidson</surname><given-names>BA</given-names></name><name><surname>Helinski</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms</article-title><source>Pain</source><year>2012</year><volume>153</volume><issue>9</issue><fpage>1871</fpage><lpage>1882</lpage><?supplied-pmid 22770843?><pub-id pub-id-type="pmid">22770843</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR, Davidson BA, et al., editors. Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. Proceedings of the 4th International Congress on Neuropathic Pain; 2013. pp 29&#x02013;35.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name><name><surname>Gross</surname><given-names>H</given-names></name><name><surname>Weinberger</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name></person-group><article-title>TNF-alpha modulation for treatment of Alzheimer&#x02019;s disease: a 6-month pilot study</article-title><source>Med Gen Med</source><year>2006</year><volume>8</volume><issue>2</issue><fpage>25</fpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name><name><surname>Gross</surname><given-names>H</given-names></name></person-group><article-title>Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer&#x02019;s disease</article-title><source>BMC Neurol</source><year>2008</year><volume>8</volume><fpage>27</fpage><?supplied-pmid 18644112?><pub-id pub-id-type="pmid">18644112</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging</article-title><source>BMC Res Notes</source><year>2009</year><volume>2</volume><fpage>28</fpage><?supplied-pmid 19284700?><pub-id pub-id-type="pmid">19284700</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name><name><surname>Britschgi-Davoodifar</surname><given-names>S</given-names></name></person-group><article-title>Perispinal TNF-alpha inhibition for discogenic pain</article-title><source>Swiss Med Wkly</source><year>2003</year><volume>133</volume><issue>11&#x02013;12</issue><fpage>170</fpage><lpage>177</lpage><?supplied-pmid 12715286?><pub-id pub-id-type="pmid">12715286</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name><name><surname>Davoodifar</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients</article-title><source>Curr Med Res Opin</source><year>2004</year><volume>20</volume><issue>7</issue><fpage>1075</fpage><lpage>1085</lpage><?supplied-pmid 15265252?><pub-id pub-id-type="pmid">15265252</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Perispinal etanercept for treatment of Alzheimer&#x02019;s disease</article-title><source>Curr Alzheimer Res</source><year>2007</year><volume>4</volume><issue>5</issue><fpage>550</fpage><lpage>552</lpage><?supplied-pmid 18220520?><pub-id pub-id-type="pmid">18220520</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>WS</given-names></name></person-group><article-title>Perispinal etanercept: potential as an Alzheimer therapeutic</article-title><source>J Neuroinflamm</source><year>2008</year><volume>5</volume><fpage>3</fpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maudsley</surname><given-names>S</given-names></name><name><surname>Chadwick</surname><given-names>W</given-names></name></person-group><article-title>Progressive and unconventional pharmacotherapeutic approaches to Alzheimer&#x02019;s disease therapy</article-title><source>Curr Alzheimer Res</source><year>2012</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>4</lpage><?supplied-pmid 22329648?><pub-id pub-id-type="pmid">22329648</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer&#x02019;s disease</article-title><source>Curr Alzheimer Res</source><year>2012</year><volume>9</volume><issue>1</issue><fpage>99</fpage><lpage>109</lpage><?supplied-pmid 22191562?><pub-id pub-id-type="pmid">22191562</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name><name><surname>Dhandapani</surname><given-names>KM</given-names></name><name><surname>Folkersma</surname><given-names>H</given-names></name><name><surname>Butterworth</surname><given-names>RF</given-names></name><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence</article-title><source>CNS Drugs</source><year>2014</year><volume>28</volume><issue>8</issue><fpage>679</fpage><lpage>697</lpage><?supplied-pmid 24861337?><pub-id pub-id-type="pmid">24861337</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>D</given-names></name></person-group><article-title>INMiND: getting to the bottom of neuroinflammation</article-title><source>Lancet Neurol</source><year>2013</year><volume>12</volume><issue>12</issue><fpage>1135</fpage><lpage>1136</lpage><?supplied-pmid 24229613?><pub-id pub-id-type="pmid">24229613</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">NEURON. Call for proposals for &#x0201c;European Research Projects on Neuroinflammation&#x0201d;, NEURON. 2014. <ext-link ext-link-type="uri" xlink:href="http://www.neuron-eranet.eu/en/522.php">http://www.neuron-eranet.eu/en/522.php</ext-link>. Accessed 9 Oct 2014.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ransohoff</surname><given-names>R</given-names></name></person-group><article-title>Call for papers: Neurology: Neuroimmunology and Neuroinflammation, a new neurology journal</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>648</fpage><lpage>649</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camara</surname><given-names>ML</given-names></name><name><surname>Corrigan</surname><given-names>F</given-names></name><name><surname>Jaehne</surname><given-names>EJ</given-names></name><name><surname>Jawahar</surname><given-names>MC</given-names></name><name><surname>Anscomb</surname><given-names>H</given-names></name><name><surname>Baune</surname><given-names>BT</given-names></name></person-group><article-title>Effects of centrally administered etanercept on behaviour, microglia and astrocytes in mice following a peripheral immune challenge</article-title><source>Neuropsychopharmacology</source><year>2014</year><?supplied-pmid 25103178?><pub-id pub-id-type="pmid">25103178</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>A</given-names></name><name><surname>Axmann</surname><given-names>R</given-names></name><name><surname>Rech</surname><given-names>J</given-names></name><name><surname>Finzel</surname><given-names>S</given-names></name><name><surname>Heindl</surname><given-names>C</given-names></name><name><surname>Kreitz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><issue>9</issue><fpage>3731</fpage><lpage>3736</lpage><?supplied-pmid 21245297?><pub-id pub-id-type="pmid">21245297</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Schaefer A, Burmann I, Regenthal R, Arelin K, Barth C, Pampel A, et al. Serotonergic modulation of intrinsic functional connectivity. Cur Biol. 2014. doi:10.1016/j.cub.2014.08.024.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Perispinal etanercept: a new therapeutic paradigm in neurology</article-title><source>Expert Rev Neurother</source><year>2010</year><volume>10</volume><issue>6</issue><fpage>985</fpage><lpage>1002</lpage><?supplied-pmid 20518613?><pub-id pub-id-type="pmid">20518613</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases</article-title><source>CNS Drugs</source><year>2011</year><volume>25</volume><issue>2</issue><fpage>145</fpage><lpage>155</lpage><?supplied-pmid 21254790?><pub-id pub-id-type="pmid">21254790</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>NM</given-names></name><name><surname>Reyzin</surname><given-names>G</given-names></name><name><surname>Rodriguez-Romanacce</surname><given-names>H</given-names></name><name><surname>Depuy</surname><given-names>V</given-names></name></person-group><article-title>Selective TNF inhibition for chronic stroke and traumatic brain injury : an observational study involving 629 consecutive patients treated with perispinal etanercept</article-title><source>CNS Drugs</source><year>2012</year><volume>26</volume><issue>12</issue><fpage>1051</fpage><lpage>1070</lpage><?supplied-pmid 23100196?><pub-id pub-id-type="pmid">23100196</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name><name><surname>Gross</surname><given-names>H</given-names></name></person-group><article-title>Rapid cognitive improvement in Alzheimer&#x02019;s disease following perispinal etanercept administration</article-title><source>J Neuroinflamm</source><year>2008</year><volume>5</volume><fpage>2</fpage></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rech</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>A</given-names></name><name><surname>Finzel</surname><given-names>S</given-names></name><name><surname>Kreitz</surname><given-names>S</given-names></name><name><surname>Sergeeva</surname><given-names>M</given-names></name><name><surname>Englbrecht</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><issue>2</issue><fpage>325</fpage><lpage>333</lpage><?supplied-pmid 23238986?><pub-id pub-id-type="pmid">23238986</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Tumor necrosis factor-alpha: presynaptic sensitivity is modified after antidepressant drug administration</article-title><source>Brain Res</source><year>1994</year><volume>665</volume><issue>2</issue><fpage>293</fpage><lpage>299</lpage><?supplied-pmid 7895065?><pub-id pub-id-type="pmid">7895065</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Noble</surname><given-names>BK</given-names></name><name><surname>Wright</surname><given-names>JR</given-names></name><name><surname>Gorfien</surname><given-names>JL</given-names></name><name><surname>Heffner</surname><given-names>RR</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration</article-title><source>J Neuroimmunol</source><year>1997</year><volume>79</volume><issue>1</issue><fpage>84</fpage><lpage>90</lpage><?supplied-pmid 9357451?><pub-id pub-id-type="pmid">9357451</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A</given-names></name></person-group><article-title>Epilepsy and inflammation in the brain: overview and pathophysiology</article-title><source>Epilepsy Curr</source><year>2014</year><volume>14</volume><issue>1 Suppl</issue><fpage>3</fpage><lpage>7</lpage><?supplied-pmid 24955068?><pub-id pub-id-type="pmid">24955068</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name><name><surname>Rodriguez-Romanacce</surname><given-names>H</given-names></name><name><surname>Levine</surname><given-names>A</given-names></name><name><surname>Ignatowski</surname><given-names>TA</given-names></name><name><surname>Spengler</surname><given-names>RN</given-names></name></person-group><article-title>Immediate neurological recovery following perispinal etanercept years after brain injury</article-title><source>Clin Drug Investig</source><year>2014</year><volume>34</volume><issue>5</issue><fpage>361</fpage><lpage>366</lpage><?supplied-pmid 24647830?><pub-id pub-id-type="pmid">24647830</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedger</surname><given-names>LM</given-names></name><name><surname>McDermott</surname><given-names>MF</given-names></name></person-group><article-title>TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants&#x02014;past, present and future</article-title><source>Cytokine Growth Factor Rev</source><year>2014</year></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pribiag</surname><given-names>H</given-names></name><name><surname>Stellwagen</surname><given-names>D</given-names></name></person-group><article-title>Neuroimmune regulation of homeostatic synaptic plasticity</article-title><source>Neuropharmacology</source><year>2014</year><volume>78</volume><fpage>13</fpage><lpage>22</lpage><?supplied-pmid 23774138?><pub-id pub-id-type="pmid">23774138</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmos</surname><given-names>G</given-names></name><name><surname>Llado</surname><given-names>J</given-names></name></person-group><article-title>Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity</article-title><source>Mediat inflamm</source><year>2014</year><volume>2014</volume><fpage>861231</fpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>R</given-names></name></person-group><article-title>Targeting TNF: a therapeutic strategy for Alzheimer&#x02019;s disease</article-title><source>Drug Discov Today</source><year>2014</year></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santello</surname><given-names>M</given-names></name><name><surname>Volterra</surname><given-names>A</given-names></name></person-group><article-title>TNF-alpha in synaptic function: switching gears</article-title><source>Trends Neurosci</source><year>2012</year><volume>35</volume><issue>10</issue><fpage>638</fpage><lpage>647</lpage><?supplied-pmid 22749718?><pub-id pub-id-type="pmid">22749718</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Whitlock DR. Comment on: &#x0201c;Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence&#x0201d;. CNS Drugs. 2014. doi:10.1007/s40263-014-0211-1.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>AB</given-names></name></person-group><article-title>The environment and disease: association or causation?</article-title><source>Proc R Soc Med</source><year>1965</year><volume>58</volume><fpage>295</fpage><lpage>300</lpage><?supplied-pmid 14283879?><pub-id pub-id-type="pmid">14283879</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howick</surname><given-names>J</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Aronson</surname><given-names>JK</given-names></name></person-group><article-title>The evolution of evidence hierarchies: what can Bradford Hill&#x02019;s &#x02018;guidelines for causation&#x02019; contribute?</article-title><source>J R Soc Med</source><year>2009</year><volume>102</volume><issue>5</issue><fpage>186</fpage><lpage>194</lpage><?supplied-pmid 19417051?><pub-id pub-id-type="pmid">19417051</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>BJ</given-names></name><name><surname>Giesbrecht</surname><given-names>G</given-names></name><name><surname>Shannon</surname><given-names>S</given-names></name><name><surname>McLeod</surname><given-names>K</given-names></name></person-group><article-title>Evaluating treatments in health care: the instability of a one-legged stool</article-title><source>BMC Med Res Methodol</source><year>2011</year><volume>11</volume><fpage>65</fpage><?supplied-pmid 21569350?><pub-id pub-id-type="pmid">21569350</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JK</given-names></name></person-group><article-title>Understanding evidence-based medicine: a primer</article-title><source>Am J Obstet Gynecol</source><year>2001</year><volume>185</volume><issue>2</issue><fpage>275</fpage><lpage>278</lpage><?supplied-pmid 11518879?><pub-id pub-id-type="pmid">11518879</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Chalmers</surname><given-names>I</given-names></name><name><surname>Rawlins</surname><given-names>M</given-names></name><name><surname>McCulloch</surname><given-names>P</given-names></name></person-group><article-title>When are randomised trials unnecessary? Picking signal from noise.</article-title><source>BMJ</source><year>2007</year><volume>334</volume><issue>7589</issue><fpage>349</fpage><lpage>351</lpage><?supplied-pmid 17303884?><pub-id pub-id-type="pmid">17303884</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. 2011. <ext-link ext-link-type="uri" xlink:href="http://www.cebm.net/index.aspx?o=5653">http://www.cebm.net/index.aspx?o=5653</ext-link>. Accessed 9 Oct 2014.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeten</surname><given-names>D</given-names></name><name><surname>van Hagen</surname><given-names>PM</given-names></name></person-group><article-title>Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?</article-title><source>Ann Rheum Dis</source><year>2010</year><volume>69</volume><issue>12</issue><fpage>2067</fpage><lpage>2073</lpage><?supplied-pmid 20705637?><pub-id pub-id-type="pmid">20705637</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">US FDA. Guidance for clinical investigators, spon`sors, and IRBs. Investigational new drug applications (INDs)&#x02014;determining whether human research studies can be conducted without an IND. 2013. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/Guidances/UCM229175.pdf">http://www.fda.gov/downloads/Drugs/Guidances/UCM229175.pdf</ext-link>. Accessed 9 Oct 2014.</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dacks</surname><given-names>PA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Fillit</surname><given-names>HM</given-names></name></person-group><article-title>Evidence needs to be translated, whether or not it is complete</article-title><source>JAMA Neurol</source><year>2014</year><volume>71</volume><issue>2</issue><fpage>137</fpage><lpage>138</lpage><?supplied-pmid 24297103?><pub-id pub-id-type="pmid">24297103</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howick</surname><given-names>J</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Aronson</surname><given-names>JK</given-names></name></person-group><article-title>Evidence-based mechanistic reasoning</article-title><source>J R Soc Med</source><year>2010</year><volume>103</volume><issue>11</issue><fpage>433</fpage><lpage>441</lpage><?supplied-pmid 21037334?><pub-id pub-id-type="pmid">21037334</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concato</surname><given-names>J</given-names></name></person-group><article-title>Observational versus experimental studies: what&#x02019;s the evidence for a hierarchy?</article-title><source>NeuroRx</source><year>2004</year><volume>1</volume><issue>3</issue><fpage>341</fpage><lpage>347</lpage><?supplied-pmid 15717036?><pub-id pub-id-type="pmid">15717036</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concato</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Horwitz</surname><given-names>RI</given-names></name></person-group><article-title>Randomized, controlled trials, observational studies, and the hierarchy of research designs</article-title><source>N Engl J Med</source><year>2000</year><volume>342</volume><issue>25</issue><fpage>1887</fpage><lpage>1892</lpage><?supplied-pmid 10861325?><pub-id pub-id-type="pmid">10861325</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trudeau</surname><given-names>DL</given-names></name></person-group><article-title>The value of observational studies in neurotherapy</article-title><source>J Neurother</source><year>2001</year><volume>4</volume><issue>3</issue><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>J</given-names></name><name><surname>Mackenzie</surname><given-names>FJ</given-names></name></person-group><article-title>The randomized controlled trial: gold standard, or merely standard?</article-title><source>Perspect Biol Med</source><year>2005</year><volume>48</volume><issue>4</issue><fpage>516</fpage><lpage>534</lpage><?supplied-pmid 16227664?><pub-id pub-id-type="pmid">16227664</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demonaco</surname><given-names>HJ</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Hippel</surname><given-names>E</given-names></name></person-group><article-title>The major role of clinicians in the discovery of off-label drug therapies</article-title><source>Pharmacotherapy</source><year>2006</year><volume>26</volume><issue>3</issue><fpage>323</fpage><lpage>332</lpage><?supplied-pmid 16503712?><pub-id pub-id-type="pmid">16503712</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name></person-group><article-title>The value of drug repositioning in the current pharmaceutical market</article-title><source>Drug News Perspect</source><year>2009</year><volume>22</volume><issue>2</issue><fpage>119</fpage><lpage>125</lpage><?supplied-pmid 19330170?><pub-id pub-id-type="pmid">19330170</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>MJ</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Long-Fox</surname><given-names>A</given-names></name><name><surname>Charles</surname><given-names>P</given-names></name><name><surname>Bijl</surname><given-names>H</given-names></name><etal/></person-group><article-title>Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8930</issue><fpage>1125</fpage><lpage>1127</lpage><?supplied-pmid 7934495?><pub-id pub-id-type="pmid">7934495</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sackett</surname><given-names>DL</given-names></name><name><surname>Rosenberg</surname><given-names>WM</given-names></name><name><surname>Gray</surname><given-names>JA</given-names></name><name><surname>Haynes</surname><given-names>RB</given-names></name><name><surname>Richardson</surname><given-names>WS</given-names></name></person-group><article-title>Evidence based medicine: what it is and what it isn&#x02019;t</article-title><source>BMJ</source><year>1996</year><volume>312</volume><issue>7023</issue><fpage>71</fpage><lpage>72</lpage><?supplied-pmid 8555924?><pub-id pub-id-type="pmid">8555924</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group><article-title>Case reports in an evidence-based world</article-title><source>J R Soc Med</source><year>1999</year><volume>92</volume><issue>4</issue><fpage>159</fpage><lpage>163</lpage><?supplied-pmid 10450190?><pub-id pub-id-type="pmid">10450190</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group><article-title>In defense of case reports and case series</article-title><source>Ann Intern Med</source><year>2001</year><volume>134</volume><issue>4</issue><fpage>330</fpage><lpage>334</lpage><?supplied-pmid 11182844?><pub-id pub-id-type="pmid">11182844</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiene</surname><given-names>H</given-names></name><name><surname>Hamre</surname><given-names>HJ</given-names></name><name><surname>Kienle</surname><given-names>GS</given-names></name></person-group><article-title>In support of clinical case reports: a system of causality assessment</article-title><source>Glob Adv Health Med</source><year>2013</year><volume>2</volume><issue>2</issue><fpage>64</fpage><lpage>75</lpage><?supplied-pmid 24416665?><pub-id pub-id-type="pmid">24416665</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GC</given-names></name><name><surname>Pell</surname><given-names>JP</given-names></name></person-group><article-title>Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7429</issue><fpage>1459</fpage><lpage>1461</lpage><?supplied-pmid 14684649?><pub-id pub-id-type="pmid">14684649</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism</article-title><source>Medscape J Med</source><year>2008</year><volume>10</volume><issue>6</issue><fpage>135</fpage><?supplied-pmid 18679537?><pub-id pub-id-type="pmid">18679537</pub-id></element-citation></ref><ref id="CR62"><label>62.
</label><mixed-citation publication-type="other">Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clin Drug Invest 2014; 34(5):361-66.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>SC</given-names></name><name><surname>Bastos-Pereira</surname><given-names>AL</given-names></name><name><surname>Fraga</surname><given-names>D</given-names></name><name><surname>Chichorro</surname><given-names>JG</given-names></name><name><surname>Zampronio</surname><given-names>AR</given-names></name></person-group><article-title>Etanercept reduces thermal and mechanical orofacial hyperalgesia following inflammation and neuropathic injury</article-title><source>Eur J Pain</source><year>2014</year><volume>18</volume><issue>7</issue><fpage>957</fpage><lpage>967</lpage><?supplied-pmid 24399698?><pub-id pub-id-type="pmid">24399698</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>SP</given-names></name><name><surname>Bogduk</surname><given-names>N</given-names></name><name><surname>Dragovich</surname><given-names>A</given-names></name><name><surname>Buckenmaier</surname><given-names>CC</given-names><suffix>3rd</suffix></name><name><surname>Griffith</surname><given-names>S</given-names></name><name><surname>Kurihara</surname><given-names>C</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica</article-title><source>Anesthesiology</source><year>2009</year><volume>110</volume><issue>5</issue><fpage>1116</fpage><lpage>1126</lpage><?supplied-pmid 19387178?><pub-id pub-id-type="pmid">19387178</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>BJ</given-names></name><name><surname>Ludbrook</surname><given-names>GL</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Cousins</surname><given-names>M</given-names></name><name><surname>Mitchell</surname><given-names>B</given-names></name><name><surname>Jaros</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation</article-title><source>Spine</source><year>2013</year><volume>38</volume><issue>23</issue><fpage>1986</fpage><lpage>1994</lpage><?supplied-pmid 24165696?><pub-id pub-id-type="pmid">24165696</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Holmes C, Butchart J, Wolfe L, Davies L, Dodge S, Lewsey I, et al. The safety and tolerability of etanercept in Alzheimer&#x02019;s disease (STEADI-09): a phase II double blind randomised placebo controlled trial 2014. Copenhagen: Alzheimer&#x02019;s Association International Conference; 2014.</mixed-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwatsuki</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Ota</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Natsume</surname><given-names>T</given-names></name><name><surname>Kurimoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain</article-title><source>PloS One</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>e57721</fpage><?supplied-pmid 23469058?><pub-id pub-id-type="pmid">23469058</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Shubayev</surname><given-names>VI</given-names></name><name><surname>Myers</surname><given-names>RR</given-names></name></person-group><article-title>Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve</article-title><source>Neuroscience</source><year>2009</year><volume>160</volume><issue>2</issue><fpage>492</fpage><lpage>500</lpage><?supplied-pmid 19250961?><pub-id pub-id-type="pmid">19250961</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtori</surname><given-names>S</given-names></name><name><surname>Miyagi</surname><given-names>M</given-names></name><name><surname>Eguchi</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>G</given-names></name><name><surname>Orita</surname><given-names>S</given-names></name><name><surname>Ochiai</surname><given-names>N</given-names></name><etal/></person-group><article-title>Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study</article-title><source>Spine</source><year>2012</year><volume>37</volume><issue>6</issue><fpage>439</fpage><lpage>444</lpage><?supplied-pmid 22020607?><pub-id pub-id-type="pmid">22020607</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmarker</surname><given-names>K</given-names></name><name><surname>Rydevik</surname><given-names>B</given-names></name></person-group><article-title>Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica</article-title><source>Spine</source><year>2001</year><volume>26</volume><issue>8</issue><fpage>863</fpage><lpage>869</lpage><?supplied-pmid 11317106?><pub-id pub-id-type="pmid">11317106</pub-id></element-citation></ref><ref id="CR71"><label>71.
</label><mixed-citation publication-type="other">Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal administration of tumor necrosis factor-alpha inhibitor, etanercept, clinically improves intractable discogenic low back pain. Glob Spine J. 2014. doi:10.1055/s-0034-1376544.</mixed-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>CH</given-names></name><name><surname>Tsai</surname><given-names>RY</given-names></name><name><surname>Shih</surname><given-names>MS</given-names></name><name><surname>Lin</surname><given-names>SL</given-names></name><name><surname>Tai</surname><given-names>YH</given-names></name><name><surname>Chien</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats</article-title><source>Anesth Analg</source><year>2011</year><volume>112</volume><issue>2</issue><fpage>454</fpage><lpage>459</lpage><?supplied-pmid 21081778?><pub-id pub-id-type="pmid">21081778</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>C</given-names></name><name><surname>Schafers</surname><given-names>M</given-names></name><name><surname>Marziniak</surname><given-names>M</given-names></name><name><surname>Toyka</surname><given-names>KV</given-names></name></person-group><article-title>Etanercept reduces hyperalgesia in experimental painful neuropathy</article-title><source>J Peripher Nerv Syst</source><year>2001</year><volume>6</volume><issue>2</issue><fpage>67</fpage><lpage>72</lpage><?supplied-pmid 11446385?><pub-id pub-id-type="pmid">11446385</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Perispinal etanercept for neuroinflammatory disorders</article-title><source>Drug Discov Today.</source><year>2009</year><volume>14</volume><issue>3&#x02013;4</issue><fpage>168</fpage><lpage>177</lpage><?supplied-pmid 19027875?><pub-id pub-id-type="pmid">19027875</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Author&#x02019;s reply to Page. &#x0201c;Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept&#x0201d;</article-title><source>CNS Drugs</source><year>2013</year><volume>27</volume><issue>5</issue><fpage>399</fpage><lpage>402</lpage><?supplied-pmid 23580177?><pub-id pub-id-type="pmid">23580177</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name></person-group><article-title>Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults</article-title><source>Clin Ther</source><year>2003</year><volume>25</volume><issue>4</issue><fpage>1211</fpage><lpage>1218</lpage><?supplied-pmid 12809967?><pub-id pub-id-type="pmid">12809967</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Yabuki</surname><given-names>S</given-names></name><name><surname>Sekiguchi</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Konno</surname><given-names>S</given-names></name></person-group><article-title>Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat</article-title><source>Eur Spine J</source><year>2011</year><volume>20</volume><issue>11</issue><fpage>1877</fpage><lpage>1884</lpage><?supplied-pmid 21633793?><pub-id pub-id-type="pmid">21633793</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanella</surname><given-names>JM</given-names></name><name><surname>Burright</surname><given-names>EN</given-names></name><name><surname>Hildebrand</surname><given-names>K</given-names></name><name><surname>Hobot</surname><given-names>C</given-names></name><name><surname>Cox</surname><given-names>M</given-names></name><name><surname>Christoferson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model</article-title><source>Spine</source><year>2008</year><volume>33</volume><issue>3</issue><fpage>227</fpage><lpage>234</lpage><?supplied-pmid 18303453?><pub-id pub-id-type="pmid">18303453</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>EL</given-names></name></person-group><article-title>Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports</article-title><source>Clin Ther</source><year>2003</year><volume>25</volume><issue>8</issue><fpage>2279</fpage><lpage>2288</lpage><?supplied-pmid 14512134?><pub-id pub-id-type="pmid">14512134</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name><name><surname>Vega</surname><given-names>CP</given-names></name></person-group><article-title>The cerebrospinal venous system: anatomy, physiology, and clinical implications</article-title><source>Med Gen Med</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>53</fpage></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobinick</surname><given-names>E</given-names></name></person-group><article-title>Tumour necrosis factor modulation for treatment of Alzheimer&#x02019;s disease: rationale and current evidence</article-title><source>CNS Drugs</source><year>2009</year><volume>23</volume><issue>9</issue><fpage>713</fpage><lpage>725</lpage><?supplied-pmid 19689163?><pub-id pub-id-type="pmid">19689163</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><mixed-citation publication-type="other">Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014.</mixed-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Ye J, Jiang R, Cui M, Zhu B, Sun L, Wang Y, et al. Etanercept reduces neuroinflammation and lethality in mouse model of Japanese encephalitis. J Infect Dis. 2014;210(6):875-89.</mixed-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Winkelstein</surname><given-names>BA</given-names></name><name><surname>Allen</surname><given-names>KD</given-names></name><name><surname>Setton</surname><given-names>LA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Shapiro</surname><given-names>IM</given-names></name><name><surname>Risbud</surname><given-names>MV</given-names></name></person-group><article-title>Chapter 19: intervertebral disc herniation: pathophysiology and emerging therapies</article-title><source>The intervertebral disc</source><year>2014</year><publisher-loc>Wien</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="other">Wilcox KS, Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy? Adv Exp Med Biol. 2014;813:169-83.</mixed-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Research progress in traumatic brain penumbra</article-title><source>Chin Med J</source><year>2014</year><volume>127</volume><issue>10</issue><fpage>1964</fpage><lpage>1968</lpage><?supplied-pmid 24824264?><pub-id pub-id-type="pmid">24824264</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>ET</given-names></name></person-group><article-title>Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense</article-title><source>Exp Neurol</source><year>2014</year><volume>258C</volume><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">25017887</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Viviani B, Boraso M, Marchetti N, Marinovich M. Perspectives on neuroinflammation and excitotoxicity: a neurotoxic conspiracy? Neurotoxicology. 2014;43:10-20.</mixed-citation></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Topdag M, Iseri M, Topdag DO, Kokturk S, Ozturk M, Iseri P. The effect of etanercept and methylprednisolone on functional recovery of the facial nerve after crush injury. Otol Neurotol. 2014;35(7):1277-83.</mixed-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Lista</surname><given-names>S</given-names></name><name><surname>Levey</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer&#x02019;s disease</article-title><source>J Alzheimer&#x02019;s Dis</source><year>2014</year><volume>41</volume><issue>3</issue><fpage>877</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">24685635</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014;25(2):131-7.</mixed-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtori</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>G</given-names></name><name><surname>Miyagi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Pathomechanisms of discogenic low back pain in humans and animal models</article-title><source>Spine J</source><year>2014</year><?supplied-pmid 24657737?><pub-id pub-id-type="pmid">24657737</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="other">Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and Alzheimer&#x02019;s disease. Rev Neurosci. 2014;25(4):509-25.</mixed-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kathirvelu</surname><given-names>B</given-names></name><name><surname>Carmichael</surname><given-names>ST</given-names></name></person-group><article-title>Intracerebral hemorrhage in mouse models: therapeutic interventions and functional recovery</article-title><source>Metab Brain Dis</source><year>2014</year><?supplied-pmid 24810632?><pub-id pub-id-type="pmid">24810632</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griessenauer</surname><given-names>CJ</given-names></name><name><surname>Raborn</surname><given-names>J</given-names></name><name><surname>Foreman</surname><given-names>P</given-names></name><name><surname>Shoja</surname><given-names>MM</given-names></name><name><surname>Loukas</surname><given-names>M</given-names></name><name><surname>Tubbs</surname><given-names>RS</given-names></name></person-group><article-title>Venous drainage of the spine and spinal cord: a comprehensive review of its history, embryology, anatomy, physiology, and pathology</article-title><source>Clin Anat</source><year>2014</year></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisondi</surname><given-names>P</given-names></name><name><surname>Sala</surname><given-names>F</given-names></name><name><surname>Alessandrini</surname><given-names>F</given-names></name><name><surname>Avesani</surname><given-names>V</given-names></name><name><surname>Zoccatelli</surname><given-names>G</given-names></name><name><surname>Beltramello</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis</article-title><source>Dermatology</source><year>2014</year><volume>228</volume><issue>1</issue><fpage>78</fpage><lpage>85</lpage><?supplied-pmid 24434720?><pub-id pub-id-type="pmid">24434720</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>ST</given-names></name><name><surname>Clarke</surname><given-names>JR</given-names></name><name><surname>Bomfim</surname><given-names>TR</given-names></name><name><surname>De Felice</surname><given-names>FG</given-names></name></person-group><article-title>Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer&#x02019;s disease</article-title><source>Alzheimer&#x02019;s dement J Alzheimer&#x02019;s Assoc</source><year>2014</year><volume>10</volume><issue>1S</issue><fpage>S76</fpage><lpage>S83</lpage></element-citation></ref><ref id="CR98"><label>98.</label><mixed-citation publication-type="other">Faingold CL. Network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold CL, Blumenfeld H, editors. Neuronal networks in brain function. CNS Disorders, and Therapeutics: Elsevier; 2014.</mixed-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Ekici MA, Uysal O, Cikriklar HI, Ozbek Z, Turgut Cosan D, Baydemir C, et al. Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injury. Eur Rev Med Pharmacol Sci. 2014;18(1):10&#x02013;27.</mixed-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detrait</surname><given-names>ER</given-names></name><name><surname>Danis</surname><given-names>B</given-names></name><name><surname>Lamberty</surname><given-names>Y</given-names></name><name><surname>Foerch</surname><given-names>P</given-names></name></person-group><article-title>Peripheral administration of an anti-TNF-alpha receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-alpha levels and memory deficits in mice</article-title><source>Neurochem Int</source><year>2014</year><?supplied-pmid 24726770?><pub-id pub-id-type="pmid">24726770</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshiyama</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Therapeutic strategies for tau mediated neurodegeneration</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>7</issue><fpage>784</fpage><lpage>795</lpage><?supplied-pmid 23085937?><pub-id pub-id-type="pmid">23085937</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J Cereb Blood Flow Metab. 2013;33(9):1376-85.</mixed-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>RJ</given-names></name><name><surname>Murray</surname><given-names>GD</given-names></name><name><surname>Teasdale</surname><given-names>GM</given-names></name><name><surname>Stewart</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Cytokine gene polymorphisms and outcome after traumatic brain injury</article-title><source>J Neurotrauma</source><year>2013</year><volume>30</volume><issue>20</issue><fpage>1710</fpage><lpage>1716</lpage><?supplied-pmid 23768161?><pub-id pub-id-type="pmid">23768161</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swardfager</surname><given-names>W</given-names></name><name><surname>Winer</surname><given-names>DA</given-names></name><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Winer</surname><given-names>S</given-names></name><name><surname>Lanctot</surname><given-names>KL</given-names></name></person-group><article-title>Interleukin-17 in post-stroke neurodegeneration</article-title><source>Neurosci Biobehav Rev</source><year>2013</year><volume>37</volume><issue>3</issue><fpage>436</fpage><lpage>447</lpage><?supplied-pmid 23370232?><pub-id pub-id-type="pmid">23370232</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice</article-title><source>Critical Care</source><year>2013</year><volume>17</volume><issue>6</issue><fpage>R301</fpage><?supplied-pmid 24373231?><pub-id pub-id-type="pmid">24373231</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>ZA</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Takada</surname><given-names>LT</given-names></name><name><surname>Sturm</surname><given-names>VE</given-names></name><name><surname>Cleveland</surname><given-names>CM</given-names></name><etal/></person-group><article-title>TDP-43 frontotemporal lobar degeneration and autoimmune disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2013</year><volume>84</volume><issue>9</issue><fpage>956</fpage><lpage>962</lpage><?supplied-pmid 23543794?><pub-id pub-id-type="pmid">23543794</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>B</given-names></name><name><surname>Dawson</surname><given-names>HN</given-names></name><name><surname>Roulhac-Wilson</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Laskowitz</surname><given-names>DT</given-names></name><name><surname>James</surname><given-names>ML</given-names></name></person-group><article-title>Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage</article-title><source>J Neuroinflamm</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>103</fpage></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>EL</given-names></name><name><surname>Carl</surname><given-names>A</given-names></name></person-group><article-title>Biochemistry of back pain</article-title><source>Open Spine J</source><year>2013</year><volume>5</volume><fpage>12</fpage><lpage>18</lpage></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>VE</given-names></name><name><surname>Stewart</surname><given-names>JE</given-names></name><name><surname>Begbie</surname><given-names>FD</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>Stewart</surname><given-names>W</given-names></name></person-group><article-title>Inflammation and white matter degeneration persist for years after a single traumatic brain injury</article-title><source>Brain</source><year>2013</year><volume>136</volume><issue>Pt 1</issue><fpage>28</fpage><lpage>42</lpage><?supplied-pmid 23365092?><pub-id pub-id-type="pmid">23365092</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><mixed-citation publication-type="other">Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, et al. Documentation of off-label use of biologics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii35&#x02013;51.</mixed-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efrati</surname><given-names>S</given-names></name><name><surname>Fishlev</surname><given-names>G</given-names></name><name><surname>Bechor</surname><given-names>Y</given-names></name><name><surname>Volkov</surname><given-names>O</given-names></name><name><surname>Bergan</surname><given-names>J</given-names></name><name><surname>Kliakhandler</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hyperbaric oxygen induces late neuroplasticity in post stroke patients: randomized, prospective trial</article-title><source>PloS One</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>e53716</fpage><?supplied-pmid 23335971?><pub-id pub-id-type="pmid">23335971</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>IA</given-names></name><name><surname>Vissel</surname><given-names>B</given-names></name></person-group><article-title>Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease</article-title><source>Biochem Pharmacol</source><year>2013</year><volume>86</volume><issue>7</issue><fpage>862</fpage><lpage>871</lpage><?supplied-pmid 23939185?><pub-id pub-id-type="pmid">23939185</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chio</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Cheong</surname><given-names>CU</given-names></name><name><surname>Chao</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha</article-title><source>BMC Neurosci</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>33</fpage><?supplied-pmid 23496862?><pub-id pub-id-type="pmid">23496862</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname><given-names>CU</given-names></name><name><surname>Chang</surname><given-names>CP</given-names></name><name><surname>Chao</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>BC</given-names></name><name><surname>Yang</surname><given-names>CZ</given-names></name><name><surname>Chio</surname><given-names>CC</given-names></name></person-group><article-title>Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-alpha contents and by stimulating newly formed neurogenesis</article-title><source>Mediat Inflamm</source><year>2013</year><volume>2013</volume><fpage>620837</fpage></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>RF</given-names></name></person-group><article-title>The liver-brain axis in liver failure: neuroinflammation and encephalopathy</article-title><source>Nature Rev Gastroenterol Hepatol</source><year>2013</year><volume>10</volume><issue>9</issue><fpage>522</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">23817325</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brambilla</surname><given-names>L</given-names></name><name><surname>Martorana</surname><given-names>F</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name></person-group><article-title>Astrocyte signaling and neurodegeneration: new insights into CNS disorders</article-title><source>Prion</source><year>2013</year><volume>7</volume><issue>1</issue><fpage>28</fpage><lpage>36</lpage><?supplied-pmid 23093800?><pub-id pub-id-type="pmid">23093800</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boivin</surname><given-names>N</given-names></name><name><surname>Menasria</surname><given-names>R</given-names></name><name><surname>Piret</surname><given-names>J</given-names></name><name><surname>Rivest</surname><given-names>S</given-names></name><name><surname>Boivin</surname><given-names>G</given-names></name></person-group><article-title>The combination of valacyclovir with an anti-TNF alpha antibody (etanercept) increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis</article-title><source>Antivir Res</source><year>2013</year><volume>100</volume><issue>3</issue><fpage>649</fpage><lpage>653</lpage><?supplied-pmid 24416771?><pub-id pub-id-type="pmid">24416771</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaylock</surname><given-names>RL</given-names></name></person-group><article-title>Immunology primer for neurosurgeons and neurologists part 2: innate brain immunity</article-title><source>Surg Neurol Int</source><year>2013</year><volume>4</volume><fpage>118</fpage><?supplied-pmid 24083053?><pub-id pub-id-type="pmid">24083053</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer&#x02019;s disease patients of northern Han Chinese descent</article-title><source>Curr Alzheimer Res</source><year>2013</year><volume>10</volume><issue>1</issue><fpage>57</fpage><lpage>62</lpage><?supplied-pmid 23368432?><pub-id pub-id-type="pmid">23368432</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>M</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Barrett</surname><given-names>JE</given-names></name><name><surname>Coyle</surname><given-names>JT</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name></person-group><article-title>Historical perspectives on the discovery and development of drugs to treat neurological disorders</article-title><source>Translational neuroscience: applications in psychiatry, neurology, and neurodevelopmental disorders</source><year>2012</year><publisher-loc>New York</publisher-loc><publisher-name>Cambridge University Press</publisher-name><fpage>129</fpage><lpage>148</lpage></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>I</given-names></name></person-group><article-title>New hope for survivors of stroke and traumatic brain injury</article-title><source>CNS Drugs</source><year>2012</year><volume>26</volume><issue>12</issue><fpage>1071</fpage><lpage>1072</lpage><?supplied-pmid 23100197?><pub-id pub-id-type="pmid">23100197</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>I</given-names></name><name><surname>Atwood</surname><given-names>C</given-names></name><name><surname>Bowen</surname><given-names>R</given-names></name><name><surname>Paz-Filho</surname><given-names>G</given-names></name><name><surname>Vissel</surname><given-names>B</given-names></name></person-group><article-title>Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer&#x02019;s disease links numerous treatment rationales</article-title><source>Pharmacol Rev</source><year>2012</year><volume>64</volume><issue>4</issue><fpage>1004</fpage><lpage>1026</lpage><?supplied-pmid 22966039?><pub-id pub-id-type="pmid">22966039</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrobjartsson</surname><given-names>A</given-names></name><name><surname>Gotzsche</surname><given-names>PC</given-names></name></person-group><article-title>Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>21</issue><fpage>1594</fpage><lpage>1602</lpage><?supplied-pmid 11372012?><pub-id pub-id-type="pmid">11372012</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974.</mixed-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hachinski</surname><given-names>V</given-names></name><name><surname>Donnan</surname><given-names>GA</given-names></name><name><surname>Gorelick</surname><given-names>PB</given-names></name><name><surname>Hacke</surname><given-names>W</given-names></name><name><surname>Cramer</surname><given-names>SC</given-names></name><name><surname>Kaste</surname><given-names>M</given-names></name><etal/></person-group><article-title>Stroke: working toward a prioritized world agenda</article-title><source>Stroke</source><year>2010</year><volume>41</volume><issue>6</issue><fpage>1084</fpage><lpage>1099</lpage><?supplied-pmid 20498453?><pub-id pub-id-type="pmid">20498453</pub-id></element-citation></ref></ref-list></back></article>